IPO - Profile


We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. Our scientific founders pioneered research on soluble amyloid-beta oligomers, or AbOs, which are globular assemblies of the amyloid-beta, or Ab, peptide that are distinct from Ab monomers and amyloid plaques. Based on decades of research and supporting evidence, AbOs More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 10,000,000 Positive High 22.47%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 01 Jul, 2021

Offer 01 Jul, 2021

Look Ahead

Lock Up Expiry Jan 01, 2022

IPO Terms

Offer Price $16.00
Offer Size 10M

Market Sentiments

Stock Price